Template:Amiodarone adverse effects: Difference between revisions
Ostermayer (talk | contribs) No edit summary |
Ostermayer (talk | contribs) (Marked this version for translation) |
||
| Line 2: | Line 2: | ||
<translate> | <translate> | ||
===[[Special:MyLanguage/Amiodarone|Amiodarone]] Adverse Effects=== | ===[[Special:MyLanguage/Amiodarone|Amiodarone]] Adverse Effects=== <!--T:1--> | ||
<!--T:2--> | |||
*[[Special:MyLanguage/Bradycardia|Bradycardia]] | *[[Special:MyLanguage/Bradycardia|Bradycardia]] | ||
*Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation. | *Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation. | ||
Latest revision as of 08:25, 20 January 2026
Amiodarone Adverse Effects
- Bradycardia
- Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation.
- Prolonged QT
- Thyrotoxicosis[1]
- Between 5-20% of patients treated with amiodarone have thyrotoxicosis (higher in areas of iodine deficiency)
- Iodine-induced hyperthyroidism
- It is thought that the iodine load may unmask hyperthyroidism in patients with multinodular goiter and subclinical Graves’ disease
- Drug-induced destructive thyroiditis
- More commonly, the cytotoxic effects of amiodarone destroy thyroid cells, resulting in a release of preformed hormone.
- Amiodarone pulmonary toxicity
- Hyperpigmentation rash
- ↑ Rosen's 8th Edition